{"protocolSection": {"identificationModule": {"nctId": "NCT01277822", "orgStudyIdInfo": {"id": "0954F-399"}, "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)", "officialTitle": "The 8 Weeks, Multicenter, Randomized, Double-blind, Clinical Study To Evaluate Efficacy Of Treatment With Losartan/Amlodipine 100/5 mg Combination Compared To Amlodipine 10 mg Monotherapy In Hypertensive Patients Who Are Not Appropriately Respond To Amlodipine 5 mg Monotherapy"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-05-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2013-04-22", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-04-22", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-01-13", "studyFirstSubmitQcDate": "2011-01-14", "studyFirstPostDateStruct": {"date": "2011-01-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-03-24", "resultsFirstSubmitQcDate": "2014-03-24", "resultsFirstPostDateStruct": {"date": "2014-04-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-06-05", "lastUpdatePostDateStruct": {"date": "2024-06-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will determine whether using losartan and amlodipine together will be non-inferior in lowering blood pressure than amlodipine alone."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "Uncontrolled hypertension", "High blood pressure", "Uncontrolled high blood pressure", "Untreated high blood pressure", "Untreated hypertension", "Essential hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 334, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Losartan/amlodipine Treatment Arm", "type": "EXPERIMENTAL", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks.", "interventionNames": ["Drug: Losartan (+) amlodipine", "Drug: Placebo to match amlodipine"]}, {"label": "Amlodipine Treatment Arm", "type": "ACTIVE_COMPARATOR", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.", "interventionNames": ["Drug: Placebo to match losartan/amlodipine tablets", "Drug: Amlodipine camsylate"]}], "interventions": [{"type": "DRUG", "name": "Losartan (+) amlodipine", "description": "One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.", "armGroupLabels": ["Losartan/amlodipine Treatment Arm"], "otherNames": ["COZAAR XQ\u2122"]}, {"type": "DRUG", "name": "Placebo to match losartan/amlodipine tablets", "description": "One tablet containing placebo, orally, once daily, for 8 weeks.", "armGroupLabels": ["Amlodipine Treatment Arm"]}, {"type": "DRUG", "name": "Amlodipine camsylate", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.", "armGroupLabels": ["Amlodipine Treatment Arm"]}, {"type": "DRUG", "name": "Placebo to match amlodipine", "description": "2 tablets containing placebo, orally, once daily, for 8 weeks.", "armGroupLabels": ["Losartan/amlodipine Treatment Arm"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8", "description": "Diastolic blood pressure was assessed at baseline and after 8 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.", "timeFrame": "Baseline and Week 8"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 4", "description": "Diastolic blood pressure was assessed at baseline and after 4 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8", "description": "Systolic blood pressure was assessed at baseline and after 8 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.", "timeFrame": "Baseline and Week 8"}, {"measure": "Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4", "description": "Systolic blood pressure was assessed at baseline and after 4 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.", "timeFrame": "Baseline and Week 4"}, {"measure": "Percentage of Participants Who Achieve Target Blood Pressure at Week 8", "description": "Participants were evaluated at Week 8 to ascertain if target blood pressure had been obtained. Criteria for meeting target BP were: sitting diastolic BP (sitDBP) \\<90mmHg or sitting systolic BP (sitSBP) \\<140mmHg) or sitDBP change more than 10mmHg from baseline or sitSBP change more than 20mmHg from baseline.", "timeFrame": "Week 8"}, {"measure": "Percentage of Participants Who Achieve Target Blood Pressure at Week 4", "description": "Participants were evaluated at Week 4 to ascertain if target blood pressure had been obtained. Criteria for meeting target BP were: sitting diastolic BP (sitDBP) \\<90mmHg or sitting systolic BP (sitSBP) \\<140mmHg) or sitDBP change more than 10mmHg from baseline or sitSBP change more than 20mmHg from baseline.", "timeFrame": "Week 4"}, {"measure": "Percentage of Participants Who Had Peripheral Edema During the Study", "description": "A pitting assessment of edema on both legs was performed at baseline and throughout the study. Participants were assessed in a seated position with both feet extended and the right ankle in a neutral dorsiflexion position. The index finger was pressed firmly over the bony prominence approximately 3cm proximal to the midpoint of the medial malleolus of the right ankle and will be held for three seconds. Presence of a residual indentation in the area after releasing pressure on the index finger was considered positive for pitting edema.", "timeFrame": "up to 8 weeks"}, {"measure": "Change From Baseline in Ankle Circumference at Week 8", "description": "Each ankle was marked with a semi-permanent marker at approximately 3 cm proximal to the midpoint of the medial malleolus to aid consistency in the performance of the measurements. Ankle circumference was measured in both ankles at baseline and Week 8 using a tension controlled tape to minimize error.", "timeFrame": "Baseline and Week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria\n\n* Participants with essential hypertension:\n\n  * who are on single drug therapy\n  * who are newly diagnosed and not yet taking any drug therapy, or have not had any drug therapy for at least 2 weeks prior to entering study\n  * who have blood pressure readings of 90mmHg \u2264 MSDBP \\< 110mmHg and 140mmHg \u2264 MSSBP \\<180mmHg after 2 weeks wash-out for patients on single agent.\n* Randomization (Visit 3)\n\n  * After dosing of amlodipine 5mg for 6 weeks, blood pressure readings are:\n\n    * 90mmHg \u2264 MSDBP \\< 110mmHg and 140mmHg \u2264 MSSBP \\< 180mmHg.\n\nExclusion criteria\n\n* Participant with MSDBP \u2265 110mmHg or MSSBP \u2265 180mmHg.\n* Participant currently taking \u2265 2 antihypertensive medications (note: fixed-dose combination medicine should be counted as the number of active ingredients).\n* Participant with known secondary hypertension of any etiology.\n* Participant with malignant hypertension or current evidence of impending or active malignant hypertension, including headache, papilledema, cardiac ischemia, or pulmonary congestion precipitated by elevated blood pressure.\n* Participant with known intolerance, contraindication or hypersensitivity to any component of dihydropyridines, angiotensin II receptor blockers.\n* Participant showing positive in pregnancy test, lactating woman, or woman who intends to get pregnant during the study period.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "FG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "168"}, {"groupId": "FG001", "numSubjects": "166"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "153"}, {"groupId": "FG001", "numSubjects": "155"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "11"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Contraindicated medication used", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Participant moved", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "BG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "168"}, {"groupId": "BG001", "value": "166"}, {"groupId": "BG002", "value": "334"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54", "spread": "10.5"}, {"groupId": "BG001", "value": "51.8", "spread": "10.6"}, {"groupId": "BG002", "value": "52.9", "spread": "10.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "78"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "126"}, {"groupId": "BG001", "value": "130"}, {"groupId": "BG002", "value": "256"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8", "description": "Diastolic blood pressure was assessed at baseline and after 8 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.", "populationDescription": "Full Analysis Set defined as all participants who were randomized, took at least 1 dose of study drug, and had blood pressure measurements at baseline and at least 1 post-randomization blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "160"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.1", "spread": "7.6"}, {"groupId": "OG001", "value": "-8.8", "spread": "7.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE_LEGACY", "nonInferiorityComment": "Non-inferiority margin was 3 mmHg as Korean Food and Drug Administration (KFDA) guidance.", "pValue": "0.1339", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "Last observed non-missing, post-baseline value was imputed for missing value. If no such value existed, the value was treated as missing in analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.0", "ciUpperLimit": "0.4", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "7.7"}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 4", "description": "Diastolic blood pressure was assessed at baseline and after 4 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.", "populationDescription": "Full Analysis Set defined as all participants who were randomized, took at least 1 dose of study drug, and had blood pressure measurements at baseline and at least 1 post-randomization blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.3", "spread": "7.8"}, {"groupId": "OG001", "value": "-10.0", "spread": "7.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.4478", "pValueComment": "No imputation for missing data was performed", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8", "description": "Systolic blood pressure was assessed at baseline and after 8 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.", "populationDescription": "Full Analysis Set defined as all participants who were randomized, took at least 1 dose of study drug, and had blood pressure measurements at baseline and at least 1 post-randomization blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "160"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.0", "spread": "12.1"}, {"groupId": "OG001", "value": "-12.7", "spread": "10.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.0717", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "Last observed non-missing, post-baseline value was imputed for missing value. If no such value existed, the value was treated as missing in analysis"}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4", "description": "Systolic blood pressure was assessed at baseline and after 4 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.", "populationDescription": "Full Analysis Set defined as all participants who were randomized, took at least 1 dose of study drug, and had blood pressure measurements at baseline and at least 1 post-randomization blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.5", "spread": "13.2"}, {"groupId": "OG001", "value": "-12.3", "spread": "10.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.8736", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "No imputation for missing data was performed"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Achieve Target Blood Pressure at Week 8", "description": "Participants were evaluated at Week 8 to ascertain if target blood pressure had been obtained. Criteria for meeting target BP were: sitting diastolic BP (sitDBP) \\<90mmHg or sitting systolic BP (sitSBP) \\<140mmHg) or sitDBP change more than 10mmHg from baseline or sitSBP change more than 20mmHg from baseline.", "populationDescription": "Full Analysis Set defined as all participants who were randomized, took at least 1 dose of study drug, and had blood pressure measurements at baseline and at least 1 post-randomization blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "160"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "63.0"}, {"groupId": "OG001", "value": "58.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.2508", "pValueComment": "No imputation for missing data was performed", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Achieve Target Blood Pressure at Week 4", "description": "Participants were evaluated at Week 4 to ascertain if target blood pressure had been obtained. Criteria for meeting target BP were: sitting diastolic BP (sitDBP) \\<90mmHg or sitting systolic BP (sitSBP) \\<140mmHg) or sitDBP change more than 10mmHg from baseline or sitSBP change more than 20mmHg from baseline.", "populationDescription": "Full Analysis Set defined as all participants who were randomized, took at least 1 dose of study drug, and had blood pressure measurements at baseline and at least 1 post-randomization blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "55.1"}, {"groupId": "OG001", "value": "61.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.2508", "pValueComment": "No imputation for missing data was performed", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Had Peripheral Edema During the Study", "description": "A pitting assessment of edema on both legs was performed at baseline and throughout the study. Participants were assessed in a seated position with both feet extended and the right ankle in a neutral dorsiflexion position. The index finger was pressed firmly over the bony prominence approximately 3cm proximal to the midpoint of the medial malleolus of the right ankle and will be held for three seconds. Presence of a residual indentation in the area after releasing pressure on the index finger was considered positive for pitting edema.", "populationDescription": "Safety Set defined as all participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "up to 8 weeks", "groups": [{"id": "OG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "166"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.5"}, {"groupId": "OG001", "value": "5.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.6646", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Ankle Circumference at Week 8", "description": "Each ankle was marked with a semi-permanent marker at approximately 3 cm proximal to the midpoint of the medial malleolus to aid consistency in the performance of the measurements. Ankle circumference was measured in both ankles at baseline and Week 8 using a tension controlled tape to minimize error.", "populationDescription": "All participants who received at least 1 dose of study drug and had available data for ankle circumference.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Losartan/Amlodipine", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks."}, {"id": "OG001", "title": "Amlodipine", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "163"}, {"groupId": "OG001", "value": "161"}]}], "classes": [{"title": "Left Ankle", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "4.7"}, {"groupId": "OG001", "value": "-0.7", "spread": "4.4"}]}]}, {"title": "Right Ankle", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "4.0"}, {"groupId": "OG001", "value": "-0.2", "spread": "4.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.7911", "pValueComment": "Left ankle: Last observed non-missing, post-baseline value was imputed for missing value. If no such value existed, the value was treated as missing in analysis", "statisticalMethod": "t-test, 2 sided"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.5933", "pValueComment": "Right ankle: Last observed non-missing, post-baseline value was imputed for missing value. If no such value existed, the value was treated as missing in analysis", "statisticalMethod": "t-test, 2 sided"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "10 weeks", "description": "Safety Set defined as all participants who received at least 1 dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Losartan 100mg/Amlodipine 5mg", "description": "One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks", "seriousNumAffected": 6, "seriousNumAtRisk": 168, "otherNumAffected": 6, "otherNumAtRisk": 168}, {"id": "EG001", "title": "Amlodipine 10mg", "description": "2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.", "seriousNumAffected": 5, "seriousNumAtRisk": 166, "otherNumAffected": 11, "otherNumAtRisk": 166}], "seriousEvents": [{"term": "ANGINA UNSTABLE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}]}, {"term": "ASTHENIA", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}]}, {"term": "ACCIDENTAL OVERDOSE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 166}]}, {"term": "EXCORIATION", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}]}, {"term": "FACIAL BONES FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}]}, {"term": "FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}]}, {"term": "THORACIC VERTEBRAL FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 166}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 166}]}, {"term": "HAEMATURIA", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}]}, {"term": "PROTEINURIA", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}]}, {"term": "UTERINE HAEMORRHAGE", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}]}, {"term": "VAGINAL HAEMORRHAGE", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}]}, {"term": "DYSPNOEA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}]}], "otherEvents": [{"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 168}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 166}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Korea, Republic of"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000017311", "term": "Amlodipine"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}